2016 - 2019 Pharmacometrics in the clinical setting for dosage adjustment of special populations
2016 - 2018 薬剤性肺線維症の分子メカニズムの解明とゲノム薬理学的解析の統合的研究
2013 - 2016 The role of the mTOR signalling pathway in placental nutrient transport.
2014 - 2015 分子標的治療薬による皮膚障害発症メカニズムに基づく新規予防・治療法の探索
2015 - 腎細胞癌患者の分子標的治療における有効性マーカーのPK-PD統合的なPGx解析
- 2014 エベロリムスによる口内炎の副作用バイオマーカーの探索
2014 - 分子標的治療薬における間質性肺炎の新規バイオマーカーの統合的探索
2012 - 2013 Search for biomarkers of adverse events as skin reaction by molecular target drugs
2013 - 分子標的治療薬の皮膚障害発症予測のためのゲノム薬理学的解析
2013 - 6. 分子標的治療薬による皮膚障害のSTAT3を標的とした新規治療法の確立
2013 - 分子標的治療薬の皮膚障害における副作用マーカーのゲノム薬理学的解析
2011 - 分子標的治療薬による皮膚障害発症メカニズムの分子生物学的解明
Show all
Papers (87):
Tomoyuki Sakaue, Kazuhiro Yamamoto, Kotaro Itohara, Yumi Kitahiro, Takahito Endo, Naoki Yokoyama, Takeshi Ishimura, Tomohiro Omura, Ikuko Yano. Population pharmacokinetics of everolimus in renal transplant recipients receiving long-term multiple immunosuppressive therapy. Drug Metabolism and Pharmacokinetics. 2024. 101009-101009
Yumi Kitahiro, Kazuhiro Yamamoto, Kimikazu Yakushijin, Takeshi Ioroi, Masaaki Tanda, Kotaro Itohara, Tomohiro Omura, Hironobu Minami, Ikuko Yano. The Efficacy of Bepotastine Besilate Compared With Hydroxyzine Pamoate for Preventing Infusion Reactions to the First Dose of Rituximab in Patients With Non-Hodgkin Lymphoma: Protocol for a Phase II, Double-Blind, Multicenter Randomized Trial. JMIR research protocols. 2024. 13. e54882
Motoko Yanagita, Satoru Muto, Hiroyuki Nishiyama, Yuichi Ando, Sumio Hirata, Kent Doi, Yutaka Fujiwara, Norio Hanafusa, Takahiro Hatta, Junichi Hoshino, et al. Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022. Clinical and experimental nephrology. 2023
Satoru Muto, Takeshi Matsubara, Takamitsu Inoue, Hiroshi Kitamura, Kazuhiro Yamamoto, Taisuke Ishii, Masahiko Yazawa, Ryohei Yamamoto, Naoto Okada, Kiyoshi Mori, et al. Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022. International journal of clinical oncology. 2023. 28. 10. 1259-1297
Hiroyuki Nishiyama, Takamitsu Inoue, Yuichi Koizumi, Yusuke Kobayashi, Hiroshi Kitamura, Kazuhiro Yamamoto, Takashi Takeda, Takehito Yamamoto, Ryohei Yamamoto, Takeshi Matsubara, et al. Chapter 2:indications and dosing of anticancer drug therapy in patients with impaired kidney function, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022. International journal of clinical oncology. 2023. 28. 10. 1298-1314
2022/06 - 日本医療薬学会 JPHCS誌論文賞 Potentially harmful excipients in neonatal medications: a multicenter nationwide observational study in Japan
2022/06 - 日本病院薬剤師会 第10回江口記念がん優秀論文賞 Safety and Efficacy of Bis-Glyceryl Ascorbate as Prophylaxis for Hand-Foot Skin Reaction: A Single-Arm, Open-Label Phase I/II Study (DGA Study)
2019/05 - 日本TDM学会 「IATDMCT学術大会」派遣賞 PHARMACOKINETIC ASSESSMENT FOR A CASE OF ALPRAZOLAM-INDUCED NEONATAL ABSTINENCE SYNDROME USING PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL
日本臨床化学会
, 日本臨床薬理学会
, International Association of Therapeutic Drug Monitoring and Clinical Toxicology
, 日本TDM学会
, 日本腎臓病薬物療法学会
, JAPANESE SOCIETY OF PHARMACEUTICAL HEALTH CARE AND SCIENCES
, THE PHARMACEUTICAL SOCIETY OF JAPAN